Mounjaro Dosage in 2026: The FDA Label Schedule
Mounjaro (tirzepatide) is a once-weekly injection approved for type 2 diabetes from age 10. Its label starts at 2,500 mcg (2.5 mg) weekly and raises the dose in 2,500 mcg (2.5 mg) steps, at least 4 weeks apart, if more glycemic control is needed, to a 15,000 mcg (15 mg) adult maximum and 10,000 mcg (10 mg) in children.
Topic: Reading Mounjaro’s FDA prescribing information
Audience: Anyone comparing a dosing schedule against its source
Reading time: 7–9 minutes
Not affiliated with Eli Lilly. Prof. Peptide is not affiliated with, endorsed by, or sponsored by Eli Lilly. Mounjaro is a registered trademark of Eli Lilly and Company. This page reports what Eli Lilly’s own prescribing information and FDA’s own publications state; it does not sell, ship, or recommend the branded product.
What Mounjaro is
Mounjaro is a brand name. Its active ingredient is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. The label states Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events. Mounjaro’s label does not cover weight reduction or obstructive sleep apnea in adults without type 2 diabetes.
Tirzepatide is also sold under a separate brand name, at different doses, for different indications — Zepbound (weight reduction and obstructive sleep apnea, without a type 2 diabetes requirement) is the same molecule with a different label. The Prof. Peptide tirzepatide profile covers how the two relate, the mechanism, and the published trial evidence across both. This page reads Mounjaro’s own label specifically, since its dosing schedule, indications, and cited trials are not identical to Zepbound’s.
What the label specifies
The table below is Mounjaro’s recommended dosage as stated in section 2.1 of its prescribing information — Eli Lilly, MOUNJARO (tirzepatide) injection prescribing information, DailyMed setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0, effective August 27, 2026.
| Step | Dosage | As specified by the label |
|---|---|---|
| Starting dosage | 2,500 mcg (2.5 mg) once weekly | The label states this dosage is for treatment initiation, not for glycemic control. |
| Dosage increase | +2,500 mcg (2.5 mg) increments | After at least 4 weeks on the current dose, if additional glycemic control is needed. |
| Maximum dosage — adults | 15,000 mcg (15 mg) once weekly | Reached only through the 2,500 mcg (2.5 mg) step-wise increases above. |
| Maximum dosage — pediatric (10 years and older) | 10,000 mcg (10 mg) once weekly | Reached only through the 2,500 mcg (2.5 mg) step-wise increases above. |
Under section 2.1, a missed dose is administered as soon as possible within 4 days (96 hours); if more than 4 days have passed, it is skipped and the next dose is administered on the regularly scheduled day. The day of weekly administration can change if at least 3 days (72 hours) separate two doses. Section 2.1 was revised in August 2026, the most recent change to the dosing section.
Section 2.2 states that Mounjaro is administered by subcutaneous injection in the abdomen or thigh, or in the back of the upper arm by another person, rotating sites with each dose. Section 12.3 gives tirzepatide an elimination half-life of approximately 5 days, “enabling once-weekly dosing,” with peak concentration 8 to 72 hours after a dose and 80% bioavailability.
Dosage forms and strengths (section 3) list four separate presentations at the same 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per-injection strengths: single-dose pens, single-dose vials, multi-dose vials, and single-patient-use KwikPens. The multi-dose vial and KwikPen each hold 4 doses at a higher total concentration than the single-dose forms (for example, the 2.5 mg strength is 10 mg/2.4 mL, 4.17 mg/mL, in the multi-dose vial or KwikPen, versus 2.5 mg/0.5 mL in the single-dose pen or vial) — the per-injection dose is identical across all four forms; only the container and total volume differ.
The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.
How do clinics prescribe Mounjaro?
Clinics describe Mounjaro as a type 2 diabetes drug that may be prescribed for weight outside its label. One states that “Mounjaro® is not FDA-approved for weight loss” and that its clinicians may prescribe it where they judge it appropriate; another describes Mounjaro and Zepbound as Eli Lilly’s branded versions of tirzepatide. No published clinic dose for Mounjaro differs from the label’s ladder above.
Clinic schedules for compounded tirzepatide, and the clinic side effects and monitoring, are on the tirzepatide dosing guide and the tirzepatide profile.
What the trials administered
Section 14 of the label (Clinical Studies) names the SURPASS trials behind Mounjaro’s approved indications — SURPASS-1 through SURPASS-5, SURPASS-PEDS, and SURPASS-CVOT. The two below are the ones the label cites for the type 2 diabetes monotherapy and add-on dosing discussed on this page. Each is graded against Prof. Peptide’s standing citation convention — a claim is attributed when a marker resolves to a named, checkable primary source. Both grade as attributed: each is named in the label itself, with a registry number checkable against ClinicalTrials.gov independent of the label.
SURPASS-1 (NCT03954834)
40-week, double-blind, placebo-controlled monotherapy trial
Arms: Placebo (mITT N=113), MOUNJARO 5,000 mcg (5 mg) (N=121), 10,000 mcg (10 mg) (N=121), 15,000 mcg (15 mg) (N=120) — adults with type 2 diabetes with inadequate glycemic control on diet and exercise alone
Endpoint reported: HbA1c change from baseline at week 40: −0.1% (placebo) vs. −1.8% (5 mg), −1.7% (10 mg), −1.7% (15 mg); all doses p<0.001 vs. placebo, adjusted for multiplicity.
Attributed — cited directly in the label's own Clinical Studies section (14.2), primary source open below.
SURPASS-2 (NCT03987919)
40-week, open-label (double-blind with respect to MOUNJARO dose assignment) trial, add-on to metformin
Arms: Semaglutide 1,000 mcg (1 mg) (mITT N=468), MOUNJARO 5,000 mcg (5 mg) (N=470), 10,000 mcg (10 mg) (N=469), 15,000 mcg (15 mg) (N=469) — adults with type 2 diabetes on stable metformin
Endpoint reported: HbA1c change from baseline at week 40: −1.9% (semaglutide 1 mg) vs. −2.0% (5 mg), −2.2% (10 mg), −2.3% (15 mg); 10 mg and 15 mg statistically significant vs. semaglutide.
Attributed — cited directly in the label's own Clinical Studies section (14.3), with a registry number checkable against ClinicalTrials.gov independent of the label.
Zepbound’s label cites a different trial program (Study 1 through Study 5, for weight reduction and obstructive sleep apnea) at different doses and different indications. Those figures belong to Zepbound’s own label, not Mounjaro’s, even though both products share the same active ingredient — the tirzepatide profile covers the trial evidence across both brands directly.
The label’s warnings and adverse events
Boxed warning: risk of thyroid C-cell tumors
The label states: “It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans”; the human relevance of the tumor finding behind the warning has not been determined.
The label states Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and instructs counseling patients on the potential risk and on symptoms such as a mass in the neck, dysphagia, dyspnea, or persistent hoarseness.
The label’s recent-changes list records a warning on diabetic retinopathy complications in patients with a history of diabetic retinopathy, revised in August 2026, alongside its warnings on severe gastrointestinal adverse reactions, acute pancreatitis, hypoglycemia with insulin or an insulin secretagogue, and acute kidney injury.
Table 1 of the label reports adverse reaction rates (≥5%) from a pool of placebo-controlled trials (718 patients exposed to Mounjaro, mean exposure 36.6 weeks):
| Adverse reaction | Placebo (N=235) | Mounjaro 5,000 mcg (5 mg) (N=237) | Mounjaro 10,000 mcg (10 mg) (N=240) | Mounjaro 15,000 mcg (15 mg) (N=241) |
|---|---|---|---|---|
| Nausea | 4% | 12% | 15% | 18% |
| Diarrhea | 9% | 12% | 13% | 17% |
| Decreased appetite | 1% | 5% | 10% | 11% |
| Vomiting | 2% | 5% | 5% | 9% |
| Constipation | 1% | 6% | 6% | 7% |
| Dyspepsia | 3% | 8% | 8% | 5% |
| Abdominal pain | 4% | 6% | 5% | 5% |
Compounding and research-grade tirzepatide
Mounjaro’s prescribing information does not mention compounding. The word does not appear anywhere in the label. Everything above this section describes a prescription drug product, manufactured by Eli Lilly and dispensed by a pharmacy against a prescription.
Research-grade tirzepatide, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is neither the branded product described above nor a pharmacy-compounded version of it. It is sold labeled for research use, not for human administration, and it is not dispensed against a prescription.
Separately from the branded label, FDA has published its own position on compounded tirzepatide. Its April 1, 2026 statement on compounding, once the national GLP-1 supply stabilized, describes the conditions under which a compounded drug can lawfully be exempt under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and states FDA’s position that a compounded product is treated as an unlawful copy of a commercially available drug when it shares the same active ingredient, a similar or easily substitutable strength, and the same route of administration — unless a prescriber documents a significant difference for an individual patient.
On April 30, 2026, FDA announced it is proposing to exclude tirzepatide, semaglutide, and liraglutide from the 503B bulks list entirely, stating it “did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances.” The public comment period on that proposal closed, and FDA has not published a final determination.
FDA also reports more than 730 adverse-event reports associated with compounded tirzepatide, notes that it is not always possible to tell whether a compounded product caused an event, and says such events are likely underreported. It reports adverse events in patients prescribed compounded semaglutide or tirzepatide “in doses beyond what is in the FDA-approved drug label,” including a faster titration schedule.
None of this changes what the label above states, and none of it describes Prof. Peptide’s vendors as compounding pharmacies — they are not. It is published here because a reader comparing a branded dosing schedule against a research-grade product should be able to see, in one place, that the two are governed by different rules, and that the regulatory status of compounded tirzepatide is itself unsettled and separate from both.
How this page differs from Zepbound’s and the tirzepatide profile
Mounjaro and Zepbound share an active ingredient, and largely share the same once-weekly, 2,500 mcg (2.5 mg) escalation mechanics and the same 4-day missed-dose window. What differs is the label built around that molecule. Mounjaro’s label is type-2-diabetes-only — glycemic control in adults and children 10 and older, and cardiovascular risk reduction in adults with type 2 diabetes at high risk — and cites the SURPASS program exclusively. Zepbound’s label covers weight reduction and obstructive sleep apnea in adults without a type 2 diabetes requirement, and cites an entirely separate set of trials (Study 1 through Study 5). A reader with type 2 diabetes and a reader without it are reading two different regulatory documents, even though the molecule injected is the same.
The tirzepatide profile is a different kind of page: it covers the molecule’s dual-agonist mechanism and the published trial evidence across both brands at once, without reading either FDA label’s escalation schedule, boxed warning, or adverse-event table in the detail this page does. This page exists because Mounjaro’s own prescribing information has figures — the missed-dose window, the SURPASS-1 and SURPASS-2 HbA1c results, the ADR percentages by dose — that the profile doesn’t report and that only Mounjaro’s own label states.
FAQ
Is Mounjaro the same as tirzepatide?
What is the starting dose on the Mounjaro label?
What is the maximum Mounjaro dose?
What happens if a dose is missed?
Does Mounjaro carry a boxed warning?
Is Mounjaro approved for weight loss?
How long does Mounjaro stay in the body?
Is compounded or research-grade tirzepatide the same as Mounjaro?
References
- Ivím Health. Mounjaro. Read 2026-11-06. https://www.ivimhealth.com/mounjaro/
- Pru. Tirzepatide vs Mounjaro and Zepbound. Read 2026-11-06. https://joinpru.com/blog/tirzepatide-vs-mounjaro-zepbound
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of 2026-10-01; read 2026-11-04. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information. DailyMed, setid d2d7da5d-ad07-4228-955f-cf7e355c8cc0, effective 2026-08-27. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug Alerts and Statements, 2026-04-01. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Press Announcements, 2026-04-30. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- ClinicalTrials.gov. A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Using Injectable Diabetes Medicines (SURPASS-1), NCT03954834. https://clinicaltrials.gov/study/NCT03954834
- ClinicalTrials.gov. A Study of Tirzepatide (LY3298176) Compared to Semaglutide in Participants With Type 2 Diabetes (SURPASS-2), NCT03987919. https://clinicaltrials.gov/study/NCT03987919
Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.
Related pages
- MOTS-c Dosage Chart: How Much MOTS-c Per Week Clinics PrescribeMOTS-c dosage as clinics publish it: 5,000–10,000 mcg (5–10 mg) per injection, 2–3 times a week, in 8–12 week cycles, with the range reported, a clinic dosage chart,…
- How Is NAD+ Dosed? The IV Trials, the Precursor Studies, and the Subcutaneous GapClinics give NAD+ by subcutaneous injection, IV infusion or nasal spray; every completed human study of injected NAD+ used IV.
- Guides — Practical Peptide Research ReferencesPractical reference guides for peptide research — injection technique, reconstitution math, syringe sizing, and research fundamentals.
Checked and updated
